Although this generalisation obscures the fact that scientifically less advanced countries may have excellent capacity in certain niche areas, there can be no doubt that African research is moribund.
Inequalities in health research contribute to inequalities in health. If science is to live up to its promise to improve health and spur development, all countries should be able to participate in research. Research must reflect national priorities and focus particularly on conditions with high burdens in Africa's populations, on evaluating interventions that aim to strengthen health systems, and on activities to convert knowledge into action. [2] [3] [4] Collaboration in research, widely represented in this theme issue, may be one vehicle for strengthening research capacity in less privileged countries. African scientists welcome collaboration with the North as a means of overcoming barriers to research and promoting exchange of ideas. Unfortunately, Africans seem less enthusiastic about collaboration between countries within their own continent. This situation may improve: the New Partnership for Africa's Development (NEPAD) is actively facilitating partnerships within Africa and with the international community. 5 Given the unequal power relations between rich and poor nations, research collaboration between them poses certain risks.
Guidelines on international partnerships in research should, however, help to minimise the danger of scientific colonialism masquerading as research collaboration. [6] [7] [8] [9] More partnerships with individuals and institutions in African countries are needed, but these should be equitable. Scientific motives and personal characteristics are not the only factors determining who collaborates with whom. Historical (often colonial) relations between countries, shared languages, and economic or security interests tend to promote contact between researchers and may provide earmarked funding for collaboration. Practical difficulties associated with countries' infrastructure, systems for information and communication, travel, foreign exchange, and safety may also influence the establishment and maintenance of scientific interaction. Such factors leave the most disadvantaged countries as the least likely to attract investment research.
The United Nation's 2005 Human Development Report noted that inequalities between and within countries are growing rapidly and that the concept of international development aid trickling down to the poorest has not worked. 10 Facilitating research partnerships that include the most disadvantaged groups will depend on targeted investments by the international community as well as by Africans. Good examples of such partnerships can be found in papers in this issue. [11] [12] [13] 
Antimalarial treatment with artemisinin combination therapy in Africa
Desirable, achievable, but not easy T he steady increase of drug resistant malaria across Africa is a crisis for which there are achievable solutions, but no easy ones. The scale of the problem is not in doubt. In Africa malaria remains one of the commonest causes of death and serious morbidity, especially for children and pregnant women.
1 Despite a decision in principle by many countries in Africa to use artemisinin based combination therapies (ACTs), most cases of malaria are still treated with monotherapy and in many areas most of these treatments will fail. 2 3 Drug combinations, rather than monotherapy, are now seen to be the best solution for treating malaria, and artemisinin based drug combinations are highly effective, with cure rates similar to that of chloroquine 30 years ago. They seem to be a good long term choice for most African countries, being safe and well tolerated (with the caveat that their safety in early pregnancy is not yet clear). Compared with other antimalarials, ACTs can reduce gametocyte carriage and thereby lower the risk of infectiousness in those who take treatment. In areas of relatively low malaria transmission in South East Asia and South Africa, widespread use of ACTs has reduced significantly the burden of malaria. 4 This benefit is likely be less marked in areas of very high transmission in Africa, where much of the reservoir of malaria infection is in asymptomatic people who never seek treatment. The primary problem with using ACTs in Africa is cost. The least expensive treatment courses currently cost more than $1, roughly 10 times that of current monotherapy. In much of the continent people have malaria several times a year, and this cost could be prohibitive both for governments and households. In response to this problem policy makers have made strenuous efforts-led by the Global Fund for HIV/AIDS, Tuberculosis and Malaria-both to increase the supply of artemisinins (alleviating a current global shortage) and to provide drugs to governments at well below their market price.
This has prompted two parallel debates which have not yet been fully resolved. One is among donor agencies on how to achieve a sustainable subsidy. Nobody who understands this issue believes that subsidy can be avoided if ACTs are to reach those who need them most. 5 What form that subsidy should take is, however, a complex technical matter on which there is no current consensus. Using these drugs will depend on a sustainable stream of funding; ministries of health in Africa are understandably wary of the
